|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:acquiredBy
|
gptkb:Grail
|
|
gptkbp:acquisitionYear
|
gptkb:Grail
|
|
gptkbp:address
|
gptkb:5200_Illumina_Way,_San_Diego,_CA_92122,_USA
|
|
gptkbp:awards
|
gptkb:Forbes_Most_Innovative_Companies
|
|
gptkbp:CEO
|
gptkb:Jacob_Thaysen
|
|
gptkbp:competitor
|
gptkb:Pacific_Biosciences
gptkb:Oxford_Nanopore_Technologies
gptkb:Thermo_Fisher_Scientific
|
|
gptkbp:divested
|
gptkb:Grail_(2024,_per_EU_order)
|
|
gptkbp:focus
|
genetic variation
biological function
|
|
gptkbp:founded
|
1998
|
|
gptkbp:founder
|
gptkb:Anthony_Czarnik
gptkb:John_Stuelpnagel
gptkb:Larry_Bock
gptkb:Mark_Chee
gptkb:David_Walt
|
|
gptkbp:headquartersLocation
|
gptkb:San_Diego,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ilumina
|
|
gptkbp:industry
|
gptkb:biotechnology
genomics
|
|
gptkbp:ISIN
|
US4523271090
|
|
gptkbp:keyPerson
|
gptkb:Francis_deSouza
gptkb:Jacob_Thaysen
gptkb:Sam_Samad
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:marketCap
|
over $30 billion (2023)
|
|
gptkbp:mission
|
improving human health by unlocking the power of the genome
|
|
gptkbp:notableProduct
|
gptkb:MiSeq
gptkb:NextSeq
gptkb:NovaSeq
gptkb:iSeq
|
|
gptkbp:numberOfEmployees
|
approximately 9,100 (2023)
|
|
gptkbp:parentCompany
|
independent (as of 2024)
|
|
gptkbp:product
|
DNA sequencing
genotyping arrays
sequencing instruments
library preparation kits
|
|
gptkbp:publiclyTraded
|
gptkb:NASDAQ
|
|
gptkbp:revenue
|
$4.5 billion (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockSymbol
|
gptkb:ILMN
|
|
gptkbp:technology
|
microarray
sequencing by synthesis
|
|
gptkbp:website
|
https://www.illumina.com/
|
|
gptkbp:bfsParent
|
gptkb:Me_Basta_Tu_Gracia
|
|
gptkbp:bfsLayer
|
6
|